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Abstract
Background: Obesity and depression are complex conditions with stronger comorbid 
relationships among women than men. Inflammation and cardiometabolic dysfunction are likely 
mechanistic candidates for increased depression risk, and their prevalence differs by sex. Whether 
these relationships extend to depressive symptoms is poorly understood. Therefore, we analyzed 
sex in associations between inflammation and metabolic syndrome (MetS) criteria on depressive 
symptomatology. Specifically, we examined whether sex positively moderates the relationship 
between depressive symptoms and inflammation among women, and whether MetS has parallel 
effects among men.
Methods: Depressive symptoms, MetS, and inflammation were assessed in 129 otherwise 
healthy adults. Depressive symptoms were assessed using Beck Depression Inventory (BDI-Ia). 
Monocyte inflammation regulation (BARIC) was quantified using flow cytometry measurement of 
TNF-α suppression by β-agonist. Moderation effects of sex on associations between BARIC, 
MetS criteria, and BDI were estimated using two-way ANOVA and linear regression, adjusting for 
BMI, and by sex subgroup analyses.
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Results: Obese individuals reported more depressive symptoms. Sex did not formally moderate 
this relationship, though BDI scores tended to differ by BMI among women, but not men, in 
subgroup analysis. Poorer inflammation control and higher MetS criteria were correlated with 
somatic depressive symptoms. Sex moderated associations between MetS criteria and somatic 
symptoms; among men, MetS criteria predicted somatic symptoms, not among women. Subgroup 
analysis further indicated that poorer inflammation control tended to be associated with higher 
somatic symptoms in women.
Conclusions: These results indicate that obesity-related inflammation and MetS factors have 
sex-specific effects on depressive symptoms in a non-clinical population. Although 
pathophysiological mechanisms underlying sex differences remain to be elucidated, our findings 
suggest that distinct vulnerabilities to depressive symptoms exist between women and men, and 
highlight the need to consider sex as a key biological variable in obesity-depression relationships. 
Future clinical studies on comorbid obesity and depression should account for sex, which may 
optimize therapeutic strategies.
1. Introduction
Depression is twice as prevalent among obese individuals, with over 40% of obese US adults 
reporting clinically-relevant depressive symptoms1, notably higher than the 7% prevalence 
rate of major depression among adults in general. Although obesity and depression are 
complex conditions, there are significant bidirectional associations between them2. Higher 
body mass index (BMI) is associated with poorer responses to classical antidepressant 
treatment3, and comorbid depression predicts unfavorable outcomes in weight-loss trials4. 
Intriguingly, meta-analyses suggest that these associations may be more pronounced in 
women than men5. Systematic reviews have identified a number of biopsychosocial 
mediators of sex differences in the links between obesity and depression, including sex 
hormones, stress, and social stigma6. While ‘sex’ generally refers to strictly biological 
attributes based on chromosomal, genetic, and hormonal factors, ‘gender’ relies on socially 
influenced identities and behavioral expressions, defined by a combination of variables, 
including biological sex. Because biology and environment reciprocally interact throughout 
the lifespan, sex differences in biological outcomes are not entirely sex-driven. Our primary 
use of the term ‘sex’ throughout this paper is for literal consistency and with 
acknowledgment of this complex interplay. For instance, sexual dimorphisms exist across 
brain structures that regulate the stress response7 and energy homeostasis8, particularly 
within the hypothalamic-pituitary-adrenal and sympathoadrenalmedullary systems, but these 
differences may be reinforced (or attenuated) by gender9. Sex differences are also observed 
in neurological pathways implicated in mental illnesses10 that are more prevalent in women, 
such as compulsive eating and major depression, which are in turn affected by gender role11. 
Despite the higher prevalence of comorbid depression among women than men in the US1, 
and recent National Institutes of Health’s effort in identifying sex as a biological variable 
(SABV), sex and gender differences in pathophysiological processes linking obesity and 
depression remain poorly understood.
Chronic, low-grade inflammation and cardiometabolic dysfunction have been identified as 
common links between obesity and depression12, and each tends to affect women and men 
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differentially. In obese persons, regardless of sex, inflammation manifests as increased 
plasma levels of pro-inflammatory cytokines (e.g., tumor necrosis factor-α [TNF-α]), 
adipokines (e.g., leptin), and C-reactive protein, an independent risk factor for 
cardiovascular disease and mortality13. As the major source of obesity-related 
inflammation14, adipose tissue macrophages accumulate with increased body weight. 
Similar to obesity, depressed patients exhibit elevated cytokine levels in serum and 
cerebrospinal fluid15, which can access the brain and reduce the bioavailability of 
monoamine neurotransmitters, such as serotonin and norepinephrine, involved in mood 
regulation16, or decrease levels of brain-derived neurotrophic factor (BDNF)17, which 
normally promotes neurogenesis and may exert antidepressant-like effects. Cytokine 
administration induces clinically-relevant depression and fatigue symptoms18, and treatment 
with TNF-α antagonist improves depressive symptomatology in patients with high 
inflammation19. Thus, inflammation is a likely candidate for the increased comorbidity with 
depression.
Notably, women generally exhibit higher levels of inflammation and greater autoimmune 
disease burden than men, and recent work suggests that women may be more vulnerable to 
inflammation-induced mood changes20. For instance, experimental endotoxin exposure 
evoked similar increases in interleukin-6 and TNF-α between women and men21, but their 
effects on depressed mood were stronger in women. Sex-specific relationships between 
inflammation and mood disturbances, particularly somatic complaints such as fatigue22, 
have also been reported. Hyper-inflammation and depressive symptoms are often linked to 
neuroendocrine dysregulation23, which modulates immune function during stress. Notably, 
women are reported to experience greater physiological stress reactivity than men24, secrete 
more pro-inflammatory cytokines in response to stressors25, and more readily develop 
glucocorticoid resistance26. Some of these effects may be attributable to endocrine 
modulation of stress-regulatory structures that contain high steroid receptor densities (e.g., 
estrogen receptor), particularly the hippocampus27. However, emerging evidence indicates 
that obesity itself produces distinct immunological changes in women, which may feed back 
upon the brain and further depress mood28. For instance, a meta-analytic review concluded 
that obesity was more strongly associated with C-reactive protein levels in women than 
men29. Adiposity may elicit higher inflammation in women due to differing adipose tissue 
metabolism30 and patterns of fat accumulation31. Despite evidence of heightened mood 
disturbances subsequent to immune activation in women, the role of obesity-associated 
inflammation in mood disturbances among women versus men remains unclear, which may 
represent a missed opportunity for targeted therapies to treat comorbid depression.
Meanwhile, men generally exhibit the metabolic syndrome (MetS) at higher rates32. MetS is 
a cluster of markers of cardiometabolic dysfunction, including dyslipidemia, hypertension, 
and hyperglycemia, that are primarily driven by obesity and bi-directionally associated with 
depression33. Among US adults, lean (BMI <25 kg/m2) men are 34% more likely to have 
MetS34 than lean women, and fewer obese men are “metabolically healthy” than obese 
women (29.2% versus 35.4%). This suggests that obesity-related MetS may be more 
prominent in men than women, leading to a question of sex-specific MetS-related mood 
disturbance. Multiple mechanisms by which MetS is associated with depressed mood have 
been described, including insulin and leptin resistance35. Studies in metabolically healthy 
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obese persons suggest that obesity-depression associations depend upon metabolic profile36. 
To date, the data on sex differences in this association have been equivocal. For example, 
somatic depressive symptoms, such as fatigue, appetite and sleep disturbances, are 
associated with abdominal obesity among both men and women, but only among men were 
symptoms also driven by cardiometabolic dysfunction in an older-aged Dutch cohort37. 
Conversely, a similar survey in Korea reported an effect of MetS on depression among 
women, but not men38. Furthermore, depressed women tend to report higher levels of 
somatic symptoms than depressed men39, suggesting sexual dimorphism in symptom 
manifestation, especially somatic symptoms. Differences in experimental methods, 
populations, or depression instruments may account for the mixed findings, and very few 
studies to our knowledge have sought to determine the independent effects of obesity and 
MetS on depressive symptoms in a sex-specific manner.
To that end, the current study examined the role of sex and obesity in associations between 
cellular inflammation, cardiometabolic dysfunction, and depressive symptoms in adults. As 
outlined above, there is growing evidence to suggest that sex-specific sensitivities to 
inflammation and cardiometabolism, particularly within the context of overweight/obesity, 
may underlie the higher incidence of comorbid depression among women or obscure MetS-
depression associations among men. The following hypotheses were tested: (1) associations 
between obesity and depressive symptomatology would be stronger in women, (2) women 
would be more susceptible to the effects of obesity-associated inflammation on depressive 
symptoms, and (3) men would be more vulnerable to the effects of MetS criteria on 
depressive symptoms.
2. Materials and methods
2.1. Participants
All participants gave informed consent to the protocol, approved by the University of 
California, San Diego Institutional Review Board. One hundred twenty-nine otherwise 
healthy, non-smoking men and women between 18-65 years were recruited from the local 
community for a larger study of the role of obesity on vascular inflammation and immune 
cell activation in stage 1 hypertension (SBP <145 mmHg; to exclude stage 2 hypertension 
with consideration for exaggerated BP in laboratory settings). Initial screening via telephone 
interviews, followed by face-to-face confirmation, established the absence of the following 
exclusion criteria: diabetes, current or recent history (<6 months) of smoking or substance 
abuse, history of cardiovascular disease (e.g., symptomatic coronary or cerebrovascular 
disease, arrhythmia, myocardial infarction, cardiomyopathy, heart failure), history of 
bronchospastic pulmonary disease, inflammatory disorders or health-related factors affecting 
immune function (e.g., vaccinations within 10 d of study visit, active infections/illness, 
immunomodulatory medication, uncontrolled thyroid disease), psychosis, major depressive 
disorder, and stage 2 clinical hypertension indicated by use of anti-hypertensive medication 
or laboratory-assessed BP ≥145/90 mmHg. A power analysis determined that a sample size 
of approximately 130 would be needed to detect small-to-medium (r=0.24) main effects 
(e.g., of BMI, MetS, and BARIC) at 80% power with two-tailed alpha=0.05 on depressive 
symptoms in linear regression models, given previous studies5,40,41. Furthermore, we 
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expected similar power to detect moderation effects by sex in these models, despite known 
challenges regarding sample size inflation required to detect moderation42, as prior meta-
analyses of sex-stratified studies have reported near zero effects of the obesity and obesity-
related risk factors in one of the two sexes5,33.
2.2. Sample collection and laboratory procedures
Average basal systolic (SBP) and diastolic blood pressures (DBP) were calculated from two 
sets of three consecutive measurements at 5-min intervals, using a Dinamap Compact BP 
monitor (Critikon, Tampa, FL). Sets were separated by 40-60 min. Standard anthropometrics 
(i.e., height, weight, hip and waist circumference) were collected via conventional tape and 
scale. BMI was calculated by weight in kg/(height in m)2 and individuals categorized by 
BMI (lean: <25 kg/m2; overweight: 25≤BMI<30 kg/m2; obese: ≥30 kg/m2). Dual x-ray 
absorptiometry was performed in a subset of men (N=25) and women (N=29) to calculate 
total body fat. Women provided first date of last menstrual period (if applicable), from 
which cycle phase was estimated (i.e., menstrual versus ovulatory), and whether they were 
currently taking hormonal contraceptives (i.e., yes versus no). Blood samples were obtained 
between 0800-1000 hr for all participants after 12h of fasting and collected in EDTA or 
heparin anti-coagulant vacutainers (BD, Franklin Lakes, NJ). Lipid profiles and glucose 
levels were assessed at UCSD Medical Center Clinical Laboratory. EDTA-treated blood 
remained on ice until plasma was separated by centrifugation and stored at −80C for 
measurement of insulin, leptin, and estradiol.
Cellular inflammation regulation assays were performed on whole blood aliquots from 
heparin vacutainers within 1h of collection. Briefly, lipopolysaccharide (LPS; 200 pg/mL) 
(E.coli 0111:B4, catalog #L4391, Sigma-Aldrich, St. Louis, MO) was added to 300 μL of 
heparinized blood and incubated for 30 min at 37°C with 5% CO2 in sterile 96-well 
polypropylene cell culture plates, along with a non-LPS-treated sample. This LPS dose was 
previously determined to elicit significant activation of monocytes, with 30-90% producing 
TNF-α40. To inhibit cytokine excretion, thus allowing for intracellular detection of TNF-α 
(cat. #502906, BioLegend, San Diego, CA), Brefeldin A (10 μg/mL, Sigma-Aldrich) was 
added to each sample for the final 3 h of incubation. Intracellular TNF-α production by 
monocytes was evaluated using multi-color flow cytometry, as previously described40. The 
proportion of CD14+/dimHLA-DR+ (CD14: cat. #301808; HLA-DR: cat. #307606, 
BioLegend, San Diego, CA) cells that were TNF-α+ was determined using FlowJo software 
(v10, TreeStar, Ashland, OR), and gates adjusted for each TNF-α-stained sample using 
fluorescence-minus-one controls.
2.3. Beta-adrenergic receptor-mediated inflammation control (BARIC)
BARIC was determined based on the inhibitory effect of isoproterenol, a non-specific β1/2-
AR agonist, on monocytic intracellular TNF-α production in LPS-stimulated blood as 
described above. In addition to LPS, blood was co-incubated with isoproterenol in 10−8 M 
final concentration and evaluated for intracellular monocyte TNF-α production. Monocyte 
β-AR-mediated responsivity to TNF-α inhibition by isoproterenol (i.e., BARIC) was 
calculated as the arithmetic difference in %TNF-α+ monocytes between LPS-treated and 
LPS+isoproterenol-treated samples. Greater BARIC values indicate greater β-AR 
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responsivity, and thus, better β-AR-mediated inflammation regulation. Smaller BARIC 
values may indicate impairment in cellular pathways that regulate inflammatory responses 
mediated by β-ARs (e.g., diminished receptor sensitivity to agonists), though BARIC itself 
does not directly reflect receptor sensitivity per se. Simply put, BARIC measures 
monocytes’ responsivity to a β-AR agonist during an inflammatory response to LPS. We 
have previously demonstrated that reduced BARIC is associated with hypertension, 
cardiovascular disease risk factors, and higher serum cytokine levels40. Given sex 
differences reported in neuroendocrine pathways7 and stress responses, examination of β-
AR-mediated inflammatory activity of monocytes is particularly relevant and functionally 
meaningful to this investigation.
2.4. Cardiometabolic assessment and sex-hormone assays
Cardiometabolic dysfunction was assessed by the number of MetS criteria satisfied 
(represented by integers 0-5) according to the International Diabetes Foundation consensus 
statement, which include (1) central obesity (≥94 cm in men, ≥80 cm in women), (2) 
hypertension (SBP≥130 or DBP≥85 mmHg), (3) hypertriglyceridemia (≥150 mg/dL), (4) 
hypoalphalipoproteinemia (HDL<50 mg/dL in men, HDL<40 in women), and (5) 
hyperglycemia (fasted glucose≥100 mg/dL). Insulin and leptin concentrations were 
measured using electro-chemiluminescent assay (cat. #K15164C, Meso Scale Diagnostics, 
Rockville, MD), and estradiol using competitive enzyme immunoassay (catalog #KGE014, 
R&D Systems, Minneapolis, MN). Sample luminescent intensities were determined using a 
Sector Imager 2400 (Meso Scale Diagnostics) and a VersaMax ELISA microplate reader 
(Molecular Devices, Sunnyvale, CA). Quantification was based on a four-parameter logistic 
curve generated per manufacturer’s protocol. The intra- and inter-assay CVs were 3.5% and 
8.1% for insulin, 3.1% and 9.5% for leptin, respectively, and the intra-assay CV was 16.1% 
for estradiol.
2.5. Measurement of depressive symptoms
Depressive symptoms were measured via the Beck Depression Inventory (BDI-Ia), a 
comprehensive and clinically robust self-report 21-item questionnaire. Each question was 
scored from 0-3, summed to a BDI total score (BDI-T), and then subcategorized into 
cognitive-affective (BDI-C) and somatic (BDI-S) depression scores based on previous 
findings that the two symptomatically distinct constructs (e.g., BDI-C: guilt, pessimism; 
BDI-S: fatigue, sleep disruption) are reliably captured by BDI-Ia43.
2.6. Statistical analysis
Statistical analyses were conducted using R v3.3.3 in RStudio (v1.0.136, Boston MA). 
Results of statistical tests were considered statistically significant if p < 0.05, and all tests 
were two-tailed. Data were visually inspected for normality and tested using the 
Kolmogorov-Smirnov test. Variables that were not normally distributed were log-
transformed (e.g., BDI scores). To explore sex and obesity differences in depressive 
symptoms, cardiometabolism, and BARIC, two-way analysis of variance (ANOVA) was 
used to determine differences by sex, BMI category, and their interactions based on F-
statistics. Multiple linear regression models were implemented to examine effects on 
depressive symptoms and quantify effect sizes (betas) and t-test regression coefficients. Age 
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and ethnicity (entered categorically as Caucasian, African-American, Asian, or Other) were 
included as covariates in all models. Simple associations among variables were assessed 
using univariate correlations of Pearson’s r across all participants. Goodness-of-fit was 
compared between models that included MetS or BARIC terms and BMI-only models using 
likelihood ratio tests to compute chi-squared statistics. MetS and BARIC were included in 
separate models to minimize case removal due to missing data (NBARIC=113; 88% of total 
cases). Serum estradiol levels were related to menstrual cycle phase (β=59.0, t40=2.79, 
p=0.007) based on self-reported date of last menstrual period. Thus, residual serum estradiol 
levels were calculated by regressing out menstrual cycle phase and hormonal contraceptive 
use, and then entered into women-only models to control for sex hormone effects on 
depressive symptoms. Family-wise error rate was corrected using Hommel’s method in 
subgroup analyses to mitigate Type I error. Model residuals were visually inspected and 
tested for homoscedasticity using the Breusch-Pagan test, and normality was assessed using 
Wilks-Shapiro test. Studentized residuals and variance inflation factors were <3.0 for all 
predictors in each model, and influence (dfbetas) and leverage (hat-value) statistics were 
assessed.
3. Results
3.1. Participant characteristics and sex-based differences
Demographic and anthropometrics.—Participants (N=129) were young to middle-
aged adults (39±12 years), of whom 30% (N=39) were obese, 40% (N=51) were overweight, 
and 30% (N=39) were lean, which closely reflects US overweight and obesity rates (CDC, 
2016). A higher proportion of women than men were obese (38% vs. 22%), but no 
significant sex differences by BMI category (χ2=6.0, p=0.20) or BMI values (men: 
28.4±5.6; women: 28.9±7.7; t119=0.47, p=0.64) were observed. Waist circumference (WC) 
and waist-hip ratio (WHR) were strongly correlated (r=0.67, t121=9.80, p<0.001) and both 
were significantly larger among men (Table 1, p<0.001). Obesity had a stronger effect on 
both WC and WHR in men than women (Table 1, p<0.05), reflecting an android pattern of 
central adiposity.
Cardiometabolism.—Men had significantly higher SBP relative to women, as well as 
higher triglyceride and lower HDL levels (Table 1). Accordingly, men tended to have higher 
MetS burden than women (19/64 versus 10/65; χ2=3.79, p=0.052), though MetS criteria 
incidence did not significantly differ by sex (Table 1). Serum insulin and leptin levels were 
elevated among obese individuals (Table 1). Leptin levels were significantly higher among 
women, even after controlling for BMI (Table 1), and positively associated with MetS 
criteria incidence (β=0.38, t=4.20, p<0.001). Despite similar sex differences in the 
relationship of WC and WHR to obesity in our sample (Table 1), sex-adjusted WC was more 
strongly predictive of cardiometabolic MetS criteria incidence than WHR (βWC=0.49, 
t=5.16, p<0.001 vs. βWC=0.32, t=3.12, p=0.002). Men had less proportional total body fat 
than women (24.5±1.6% versus 36.0±1.3%; t36=5.45, p<0.001). Nevertheless, obesity had a 
stronger effect on leptin in men versus women, such that leptin levels increased at a greater 
rate in relation to increasing BMI in men (F2,122=3.14, p=0.047) (Fig. S1).
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Inflammation and depressive mood.—In response to LPS, monocytes from men and 
women expressed similar proportions of TNF-α (55.0±1.8% versus 54.5±1.9%; t110=−0.18, 
p=0.86) and were similarly sensitive to βAR-mediated suppression of TNF-α (Table 1). For 
nearly all participants (95%), depressive symptoms ranged from minimal (BDI-T score ≤13) 
to mild (13< BDI-T ≤19). Six subjects scored in the moderate range (19< BDI-T ≤28), 
though none had a concurrent depression diagnosis. Average BDI-T score was 5.7±6.3, and 
BDI-C and BDI-S subscale scores were 2.9±3.8 and 2.8±3.1, respectively. As anticipated, 
BDI-C and BDI-S scores were intercorrelated (r=0.62, t127=8.79, p<0.001). On average, 
women scored significantly higher on the BDI-S than men, though sex differences were not 
observed on the BDI-C subscale (Table 1).
3.2. Associations between obesity, depressive symptomatology, and sex
In all participants, BMI was positively correlated with both BDI-C (r=0.23, t127=2.60, 
p=0.01) and BDI-S scores (r=0.34, t127=4.14, p<0.001). In agreement with our previous 
findings40,44, obese individuals reported more depressive symptoms than lean or overweight 
individuals (obese vs. lean: βBDI-S = 0.65, p<0.001; βBDI-C=0.54, p=0.013; obese vs. 
overweight: βBDI-S=0.42, p=0.02; βBDI-C=0.35, p=0.08). No significant differences were 
observed between lean and overweight groups (p ≥0.05).
Women reported significantly more somatic, but not cognitive, depressive symptoms than 
men (βsex=0.32, p=0.02) (Table 1). Although the effects of obesity on depressive symptoms 
were not formally moderated by sex (i.e., BMI × sex interaction) (Table 1), separate analyses 
by sex subgroups indicated that depressive symptoms tended to differ by BMI in women for 
both somatic (F2,58=3.63, padj=0.06) and cognitive-affective symptoms (F2,58=3.51, 
padj=0.073), but not men (padj≥0.10) (Fig. 1). More specifically, obese women reported more 
depressive symptoms than lean women (BDI-S: β=0.59, t=2.48, padj=0.048; BDI-C: β=0.68, 
t=2.65, padj=0.032). Symptoms did not differ between obese and overweight or overweight 
and lean women (padj≥0.10).
3.3. Sex-specific effects of cardiometabolic dysfunction on somatic depressive 
symptoms
Obese and overweight individuals had significantly higher incidence of MetS factors than 
lean individuals (obese versus lean: β=1.79, t=7.00, p<0.001; overweight vs. lean: β=0.96, 
t=4.03, p<0.001). Across all participants, MetS factors were positively correlated with 
somatic depressive symptomatology (r=0.23, t127=2.72, p=0.007), but not cognitive-affective 
symptoms (r=0.10, t127=1.08, p=0.28). Adjusting for BMI and sex, MetS factors were 
associated with BDI-S scores across the study sample (βMetS=0.15, p=0.041, Table 2) and 
explained an additional 4.7% of the variance in BDI-S (χ2=9.10, p=0.011). Stepwise 
addition of serum leptin and insulin levels into the model did not explain additional variance 
or improve model fit (χ2=0.31, p≥0.10). MetS factor incidence was also negatively 
correlated with BARIC values (r=−0.20, t111=−2.18, p=0.032) and age (r=0.25, t129=2.91, 
p=0.004), and was significantly higher in overweight/obese individuals (Table 1).
Regression models also showed that sex significantly moderated the association between 
MetS factor incidence and somatic symptoms (F1,119=5.49, p=0.021, Table 2). Analysis 
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within each sex subgroup indicated that higher MetS factor incidence was linearly associated 
with increased somatic symptoms in men (βMetS=0.20, padj=0.027), but not in women 
(padj≥0.10) (Fig. 2A). Estradiol levels were not related to BDI-S in women (padj≥0.10).
3.4. Sex-specific effects of β-adrenergic receptor mediated inflammation control on 
somatic depressive symptoms
BARIC values were negatively correlated with somatic symptoms (r=−0.22, t110=−2.36, 
p=0.02), but not cognitive-affective symptoms (r=−0.11, t110=−1.18, p=0.24), across all 
participants. BARIC was significantly lower among older individuals (βage=−0.15, t111=
−2.23, p=0.028) and tended to differ by BMI category (F2,110=2.84, p=0.06). Post hoc 
comparisons indicated that BARIC was significantly lower among obese individuals (β=
−4.88, t110=−2.32, padj=0.045) and somewhat lower among overweight compared to lean 
individuals (β=−3.49, t110=−1.72, padj=0.088), indicating poorer inflammation control in 
obesity.
BARIC values did not significantly differ between men and women (Table 1), adjusting for 
age, ethnicity, and BMI. However, beyond the effects of obesity, lower BARIC values tended 
to be associated with higher somatic depressive symptoms in all participants (βBARIC=−0.14, 
p=0.057) and explained an additional 2.1% of the variance in somatic symptoms (χ2=3.96, 
p=0.046). Sex did not significantly moderate the association between BARIC and somatic 
symptoms (F1,102=0.76, p=0.39), though analysis within each sex indicated that BARIC 
values tended to be associated with increased BDI-S scores in women (βBARIC=−0.20, t=
−2.18, padj=0.069), but not in men (padj≥0.10) (Fig. 2B, Table 2). Estradiol levels were not 
related to depressive symptoms in the women-only model (padj≥0.10).
4. Discussion
Mounting evidence indicates that obesity and depression are linked by inflammation and 
cardiometabolic dysfunction. Men and women may be differentially susceptible to these 
conditions, and thus it is critical to examine sex differences in their effects on depressive 
symptomatology. In this investigation, we found that obesity was more strongly associated 
with depressive symptomatology in women than men, which is consistent with the 
literature5,6. As hypothesized, we also found that sex moderated the depressive symptom-
cardiometabolic dysfunction relationship such that higher MetS risk factor incidence was 
linearly associated with somatic symptom scores among men, but not among women. In 
addition, poorer inflammation control tended to be associated with increased somatic 
symptoms among women, but not among men. These sexual dimorphisms in obesity-related 
biological factors that contribute to depressive mood may offer insight into potentially 
differing pathophysiological processes underlying obesity-depression comorbidity between 
men and women.
Subgroup analysis indicated that BMI-depressive symptom associations tended to occur in 
women, but not in men, which generally aligns with the literature45. It is well-recognized 
that harsher social attitudes toward obesity and stronger weight biases exist toward women6, 
which may intensify feelings of guilt and worthlessness (i.e. cognitive-affective symptoms), 
and that depressed women may report somatic symptoms (e.g., fatigue and sleep 
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disturbance) with greater frequency and intensity than depressed men46. Somatic, or 
“atypical,” symptoms of depression predict future MetS47 across sexes, which aligns with 
our cross-sectional findings, though prior studies investigating sex effects have been 
inconclusive. Of note, the MetS-somatic symptom relationship observed here controlled for 
obesity, highlighting the role of cardiometabolic pathophysiology beyond adiposity in 
depressive symptomatology.
The biological mechanisms linking MetS and depression are complex. Neuroendocrine 
regulators of energy metabolism, specifically leptin and insulin, have been associated with 
atypical depression48. Here, neither was associated with somatic symptoms, though obesity-
leptin associations were stronger among men than women, despite higher leptin levels 
among women at any given BMI. Our findings somewhat differ from a prior study that 
reported both stronger obesity-leptin relationships and greater leptin levels among women49. 
Leptin had previously been shown to predict depression onset among men50 and may exert 
these effects via leptin receptors within corticolimbic neuronal pathways or by modulating 
the hypothalamic-pituitary-adrenal axis. Multiple studies have reported longitudinal 
associations between insulin resistance or type 2 diabetes and depression51, and vice versa in 
both sexes, but have focused on clinical populations rather than depressive symptoms in 
non-clinical populations. Nevertheless, the moderating effect of sex on the MetS-depressive 
symptom association suggests distinct pathophysiological differences between women and 
men, warranting further mechanistic investigations and consideration of sex in future studies 
of the MetS-depression link.
We observed that impaired monocyte inflammation control by β-agonist was correlated with 
somatic depressive symptomatology and obesity. An emerging literature indicates that 
inflammation plays a key role in the development of neuropsychiatric comorbidities in 
obesity12. Specifically, monocytes have been implicated in relation to pro-inflammatory 
signals originating from the periphery and disrupting neuronal homeostasis. For instance, in 
diet-induced obesity, monocytes are recruited into adipose tissue and adopt an M1 
macrophage phenotype characterized by heightened TNF-α secretion52. TNF-α then 
communicates with the brain in part by stimulating the hypothalamic-pituitary-adrenal axis, 
decreasing central serotonin levels, and activating microglial cells, all of which have been 
implicated in depression. In addition, transmigration of peripheral, pro-inflammatory 
monocytes into the brain has been associated with depressive behavior in rodent models53. 
Monocyte migration is driven by adrenergic signals from the sympathetic nervous system, 
which tends to be hyperactive in depression54. Sympathetic activity was not assessed in this 
study, though the observed trend between reduced monocyte sensitivity to β-agonist and 
higher depressive symptoms likely reflect a compensatory downregulation of β-AR 
signaling secondary to autonomic imbalance. Interestingly, gene transcriptional data suggest 
that chronic stress alters β-AR-mediated signaling pathways in monocytes and increases 
pro-inflammatory monocyte subsets55. Further studies are needed to examine whether such 
alterations lead to functional differences in inflammation regulation and immunity, and 
whether they are associated with depressive symptoms.
Although sex did not moderate inflammation-depressive symptom associations, subgroup 
analyses revealed that reduced BARIC among women, but not men, tended to be associated 
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with increased somatic symptomatology. An emerging literature suggests female-specific 
sensitivity to immune activation on mood and cognitive disturbances21. Our findings support 
this hypothesis and provide initial evidence that women may be more vulnerable to somatic 
symptoms in the context of obesity-associated inflammation. While animal studies suggest 
that estrogens may be protective against inflammation56, we did not find that somatic 
symptoms were related to estradiol levels in blood plasma. However, clinical investigations 
into the protective effects of sex hormones in inflammation-mood relationships are 
warranted. It has been hypothesized that female-specific vulnerabilities to the cognitive-
behavioral effects of inflammation reflect an evolutionary trade-off: women of reproductive 
age may have benefitted from enhanced healing and pathogen exposure avoidance afforded 
by depressed mood during infection, at the expense of increased depressive disorders in 
contemporary, pro-inflammatory contexts57. Together with the trend toward stronger effects 
of obesity on depressive symptoms among women, this hypothesis highlights a potentially 
multifaceted inflammation-depression relationship in women.
Treating depression in obese individuals poses unique challenges, such as poorer 
antidepressant responses and more severe symptomatology3. Thus, pharmacological 
interventions have begun to target inflammatory and cardiometabolic pathways as 
therapeutic adjuvants to psychotherapy or conventional pharmacotherapy. Unlike cognitive-
behavioral therapy or selective serotonin reuptake inhibitor treatment, such interventions 
would require detection of cardiometabolic dysfunction or inflammation to prescribe the 
appropriate adjuvant, with consideration of patient sex, as our findings support. A review of 
randomized controlled trials, investigating depression interventions for adults with 
diabetes58, found that pharmacological antidepressant treatment improved both depressive 
symptoms and glycemic control, whereas psychological treatment alone did not affect 
glycemic outcomes. Recent work suggests that MetS may be a stronger predictor of 
depression prognosis than obesity or diet59. Our results indicate that this may be particularly 
pertinent to obese men. Therefore, targeting cardiometabolic pathways in obese persons with 
depression may optimize treatment outcomes. To that end, insulin sensitization using a 
peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist significantly improved 
depressive symptoms in patients with comorbid insulin resistance60. Integrative behavioral 
approaches to treat comorbid depression are also being explored, which involve coordinated 
strategies that address cognitive, behavioral, and weight management goals. Meta-analyses 
indicate that adherence to a Mediterranean diet is associated with decreased risk for MetS 
and incident depression61, and thus may be a particularly effective intervention for depressed 
individuals who satisfy MetS criteria. Lastly, recent studies suggest that gut microbial 
composition is altered in both obesity and depression, and that treatment with probiotic or 
prebiotic compounds produces anti-obesogenic and anti-inflammatory effects, leading to 
improvements in depressive-like behavior in rodent models62.
There are a handful of limitations in the current study. Firstly, the cross-sectional nature of 
the design limits causal interpretation of the associations among obesity, depression, 
cardiometabolic dysfunction, and inflammation. Second, we did not recruit individuals with 
clinical depression or cardiometabolic disease, but rather a medically healthy population of 
adults with a wide range of depressive symptoms and obesity/adiposity. Therefore, our 
findings cannot be directly extrapolated into populations with comorbid clinical depression. 
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However, our findings do translate to subclinical mood disturbances that are likely a 
significant barrier to adopting healthy behavior in combating obesity, which bears 
meaningful public health implications. Subclinical symptomatology often results in 
significant functional difficulties, exerts a negative impact on quality of life, and poses an 
increased risk for later development of major depression and other psychiatric conditions63. 
Another limitation is that sex-specific manifestations of depressed mood may not be 
captured by the BDI, though a recent review of sex differences in obesity-depression 
associations reported that stronger associations among women were not likely due to 
depression measurement methods45. We also acknowledge the possibility that, while 
sufficient to detect main effects, the study’s sample size may have limited statistical power 
to detect moderation (i.e., interaction) effects of sex. Our sex-stratified findings, while 
adjusted for multiple comparisons, should therefore be interpreted as differences in 
significance within men versus women, rather than significant differences between the sexes. 
Finally, somatic complaints in otherwise healthy populations may reflect impairments 
concurrent with undetected or otherwise undiagnosed medical illnesses, rather than 
depression per se. Importantly, however, participants in the present study were thoroughly 
screened and excluded if they had a history of cardiovascular disease, were stage 2 
hypertensive, or had abnormal blood cell profiles.
In conclusion, results from the present study indicate that obesity-related inflammation and 
cardiometabolic dysregulation may have sex-specific effects on somatic depressive 
symptoms in a non-clinical population. Although the pathophysiological mechanisms 
underlying sex differences in these associations remain to be elucidated, our findings 
highlight the continued need to consider sex as a key biological variable in these 
relationships. Future clinical studies on comorbid obesity and depression should therefore 
take sex into account, which will potentially optimize therapeutic strategies to treat these 
conditions.
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Figure 1. Somatic and cognitive depressive symptoms according to BMI category and sex.
Subject-wise data are shown overlaid onto box-and-whisker plots grouped by BMI category 
and sex. Subgroup analysis by sex (ANOVA) indicated that depressive symptoms tended to 
be elevated with increasing BMI in women (left panel, somatic: F2,58=3.63, padj=0.06; right 
panel, cognitive-affective: F2,58=3.51, padj=0.073), but not in men (padj≥0.10). In particular, 
linear regression revealed that obese women reported more depressive symptoms than lean 
women (BDI-S: β=0.59, t=2.48, padj=0.048; BDI-C: β=0.68, t=2.65, padj=0.032). BDI 
scores were log-transformed for normality. Points were jittered to minimize overplotting. P-
values adjusted for multiple comparisons using Hommel’s family-wise error rate correction. 
Abbreviations: BMI=body mass index; BDI-S=Beck Depression Inventory somatic subscale 
score; BDI-C=Beck Depression Inventory cognitive/affective subscale score.
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Figure 2. Somatic depressive symptoms according to sex, MetS risk factor incidence, and 
inflammation control.
(A) BDI somatic subscale scores grouped by sex, presenting with MetS risk factors. (B) BDI 
somatic subscale scores grouped by sex, according to BARIC, split by tertile for 
visualization purposes. Beta values shown derive from multivariate linear regression 
performed on log-transformed BDI-S scores, covarying for age, ethnicity, and BMI category. 
Data are presented as mean ± s.e.m. P-values adjusted (padj) using Hommel’s family-wise 
error rate correction. Abbreviations: BMI=body mass index; BDI=Beck Depression 
Inventory; MetS=Metabolic syndrome; BDI-S=Beck Depression Inventory somatic subscale 
score; BARIC=Beta-adrenergic receptor-mediated inflammation control; n.s.=not significant 
at padj<0.05.
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Table 1.
Sex- and obesity category-based differences in anthropometric, cardiometabolic, depressive, and immune 
characteristics of 129 study participants.
Men Women
Lean
N = 16
Overweight
N = 34
Obese
N = 14
Lean
N = 23
Overweight
N = 17
Obese
N = 25 Fsex FBMI Fsex × BMI
Age (yrs) 35.9 ± 3.6 43.3 ± 2.0 40.4 ± 2.2 32.1 ± 2.1 41.1 ± 3.2 38.6 ± 2.4 1.01 5.67 0.17
Waist (cm) 81.2 ± 1.7 97.4 ± 1.5 121.3 ± 3.5 78.9 ± 2.1 90.4 ± 2.5 107.9 ± 2.2 14.1a 97.6c,d 3.41
Waist-hip ratio 0.85 ± 0.01 0.94 ± 0.01 1.01 ± 0.01 0.86 ± 0.02 0.87 ± 0.02 0.88 ± 0.01 13.7a 7.29c,d 5.01
Insulin (pg/mL) 167 ± 23 297 ± 32 785 ± 146 171 ± 19 219 ± 32 516 ± 88 1.35 31.8c,d 1.47
Leptin (ng/L) 1.5 ± 0.3 6.6 ± 1.4 26.0 ± 7.1 10.2 ± 1.9 22.1 ± 3.4 50.2 ± 5.8 87.0b 43.2c,d 3.14
Glucose (mg/dL) 83.3 ± 1.7 85.9 ± 2.7 87.8 ± 4.5 74.1 ± 2.0 87.2 ± 6.4 81.1 ± 2.0 2.84 2.28 1.32
HOMA-IR 0.9 ± 0.1 1.6 ± 0.2 4.1 ± 0.9 0.8 ± 0.1 1.1 ± 0.2 2.6 ± 0.5 1.19 25.8c,d 0.90
TG (mg/dL) 98.6 ± 10.8 165 ± 35.3 117 ± 12.8 75.4 ± 10.2 88.4 ± 14.1 120 ± 13.0 8.46a 9.63d 1.98
LDL (mg/dL) 104 ± 7.8 108 ± 4.9 127 ± 10.7 87.6 ± 6.4 115 ± 7.9 115 ± 4.8 0.38 5.15 1.61
HDL (mg/dL) 58.9 ± 4.1 52.4 ± 3.3 43.3 ± 2.1 69.9 ± 4.1 57.9 ± 2.7 54.0 ± 3.1 6.99b 8.42c 0.53
Systolic BP (mmHg) 120 ± 3.3 121 ± 2.4 130 ± 2.4 103 ± 2.2 117 ± 3.6 120 ± 3.5 12.2a 6.68 1.73
Diastolic BP 
(mmHg) 72.1 ± 2.4 71.0 ± 1.4 76.4 ± 2.1 63.4 ± 1.6 70.6 ± 2.2 72.4 ± 2.3 3.79 3.74 2.04
Estradiol - - - 161 ± 17 118 ± 18 138 ± 10 - 1.10 -
BDI-T 3.8 ± 1.4 4.6 ± 0.7 7.3 ± 2.0 4.1 ± 1.0 5.2 ± 1.4 9.5 ± 1.6 3.01 5.13 0.16
BDI-S 1.4 ± 0.7 2.2 ± 0.4 3.2 ± 0.8 2.4 ± 0.6 2.3 ± 0.5 4.9 ± 0.8 5.59b 6.13c 0.56
BDI-C 2.4 ± 0.8 2.4 ± 0.5 4.1 ± 1.4 1.7 ± 0.5 2.9 ± 1.0 4.6 ± 0.9 0.64 3.30 0.56
MetS criteria met 0.75 ± 0.3 1.8 ± 0.2 2.8 ± 0.3 0.63 ± 0.1 1.3 ± 0.2 2.3 ± 0.3 0.92 24.1c,d 0.54
BARIC 32.0 ± 2.1 28.9 ± 1.6 26.6 ± 2.3 34.4 ± 2.1 31.6 ± 2.2 29.8 ± 2.0 2.12 1.16 0.12
Values presented as mean ± s.e.m. Bold values signify ANOVA F-ratio at p <0.05. Superscripts denote post-hoc t-test of predictor coefficient 
significance at p <0.05:
a
Men > women.
bWomen > men.
cObese significantly different than lean.
dOverweight significantly different than lean. Age and ethnicity included as covariates in all models.
Abbreviations: BMI=body mass index; TG=triglycerides; LDL=low density lipoprotein; HDL=high density lipoprotein; BP=blood pressure; BDI-
T=Beck Depression Inventory total score; BDI-S=Beck Depression Inventory somatic subscale score; BDI-C=Beck Depression Inventory 
cognitive/affective subscale score; MetS=Metabolic syndrome; BARIC=Beta-adrenergic receptor-mediated inflammation control.
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Table 2.
Contribution of sex, MetS factor incidence, and β-adrenergic inflammation control (BARIC) to somatic 
depressive symptoms (BDI somatic subscale score).
Dependent Variable Sex Predictors β SE t
BDI Somatic Subscale Score All participants BMI (overweight) 0.20 0.18 1.15
BMI (obese) 0.63 0.22 2.87**
Sex 0.65 0.21 3.11**
MetS 0.15 0.07 2.07*
Sex × MetS −0.24 0.10
−2.34*
Women BMI (overweight) 0.16 0.26 0.63
BMI (obese) 0.80 0.30 2.69**
MetS −0.11 0.10 −1.16
Men BMI (overweight) 0.14 0.24 0.58
BMI (obese) 0.24 0.33 0.71
MetS 0.20 0.08 2.55*
BDI Somatic Subscale Score All participants BMI (overweight) 0.14 0.18 0.81
BMI (obese) 0.61 0.19 3.24**
Sex 0.36 0.14 2.56*
BARIC −0.07 0.11 −0.63
Sex × BARIC −0.12 0.14 −0.87
Women BMI (overweight) 0.04 0.25 0.17
BMI (obese) 0.55 0.24 2.32*
BARIC −0.20 0.09
−2.18#
Men BMI (overweight) 0.26 0.26 1.02
BMI (obese) 0.67 0.31 2.16#
BARIC −0.05 0.11 −0.44
Significance of predictors within each linear regression model at
**p < 0.01,
*p < 0.05,
#p < 0.10 is shown in the table.
P-values in sex subgroup models were adjusted for family-wise error rate correction using Hommel’s method. Age and ethnicity were included as 
covariates in all models. Analyses performed using log-transformed BDI scores. Abbreviations: BMI=body mass index; BDI=Beck Depression 
Inventory; MetS=Metabolic syndrome; BARIC=Beta-adrenergic receptor-mediated inflammation control.
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